Barbara Jane O'Brien, M.D.
Department of Neuro-Oncology, Division of Cancer Medicine
About Dr. O'Brien
Dr. Barbara O’Brien is an associate professor of Neuro-Oncology at MD Anderson who specializes in the treatment of primary brain tumors, such as glioblastoma, astrocytoma and oligodendroglioma, as well as brain metastasis and leptomeningeal disease. She obtained her medical degree from St. George’s University School of Medicine and completed a clinical residency in neurology at University of Connecticut. Following a clinical fellowship in neuro-oncology at MD Anderson, she joined the faculty in 2014. Dr. O’Brien’s clinical research interests focus on finding new treatment strategies for patients diagnosed with primary brain tumors, brain metastasis or leptomeningeal disease. She has served as principal investigator on numerous clinical trials for patients with these advanced cancers and is actively involved in MD Anderson’s brain metastasis program.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | St George's University School of Medicine, Grenada, West Indies, MD, Medicine |
| 2001 | Tulane University, Newcomb College, New Orleans, LA, USA, BS, Ecology and Evolutionary Biology/Art History |
Postgraduate Training
| 2012-2014 | Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2011-2011 | Visiting Residency, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 2009-2012 | Clinical Residency, Neurology, University of Connecticut/Hartford Hospital, Farmington, CT |
| 2008-2009 | Clinical Internship, Internal Medicine, University of Connecticut, Farmington, CT |
| 2002-2003 | Post-Baccalaureate, Pre-Medical Certificate, University of Miami, Coral Gables, FL |
Board Certifications
| 2019 | Diplomate of Neuro-Oncology; United Council for Neurologic Subspecialties |
| 2012 | American Board of Psychiatry and Neurology |
Experience & Service
Academic Appointments
Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2021
Instructor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2014
Administrative Appointments/Responsibilities
Division Wellness Lead, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Wellness Lead, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
EPIC Electronic Health Record Officer, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - Present
Chief Resident, Neurology Residency Program, The University of Connecticut/Hartford Hospital, Hartford, CT, 2011 - 2012
Other Appointments/Responsibilities
Member, Neuro-Oncology Clinical Research (NOCR) Task Force, Houston, 2022 - Present
Review Committee Chair, Disease Site Clinical Trials Protocol, Houston, 2022 - Present
Department Representative, Elect, Faculty Wellness, Houston, 2022 - Present
Co-Leader, Cancer Neurosciences, Neuro Neoplasms, Initiative #2 (Liquid Biopsies), Houston, 2022 - Present
Moonshot Scientific Seminar: Glioblastoma Moon Shot – Liquid Biopsy in Glioma, MD Anderson Cancer Center, Houston, TX, 2020 - 2020
Multidisciplinary team provider (neurology/medical-oncology), Brain Metastasis Clinic, MD Anderson Cancer Center, Houston, 2019 - Present
Founding member, Wellness Committee, Society of Neuro-Oncology, Houston, TX, 2018 - 2020
Member, LANO international response assessment committee for Leptomeningeal (LMD), RANO, Houston, TX, 2018 - Present
Member, Question Review Panel, ASCO University, Houston, TX, 2017 - 2019
Member, Residency Rotation Review Committee, Hartford Hospital, Hartford, CT, 2011 - 2012
Moderator, Neurology board examination preparation course, University of Connecticut, Farmington, CT, 2011 - 2012
Neurology program representative, University of Connecticut Resident Forum, Farmington, CT, 2010 - 2012
Institutional Committee Activities
Co-Chair, Faculty Senate Welfare Committee Workload Task Force, 2023 - Present
Focus Group, Transformation of Work best practices, sponsored by Office of Workplace, Culture and Infrastructure, 2023 - 2023
Committee Member, Mid-Career Faculty Committee, 2022 - Present
Committee Member, Faculty Vitality & Engagement, 2021 - Present
Committee Member, Women Faculty Focus Group, 2021 - 2021
Member, Scientific (Clinical) Review Committee (SRC) 2, 2020 - Present
Executive Committee Member, Brain Tumor Center, 2018 - Present
Member, Neuro-Oncology Chair Search Advisory Committee, 2018 - 2020
Member, Radiation Oncology Division Head Search Committee, 2018 - 2020
Liaison, Scripps MD Anderson Neuro-Oncology, Cancer Network, 2018 - Present
Promotion and Tenure Subcommittee, Focus on Junior Faculty Committee, 2018 - Present
Member, Brain Metastasis Clinical Workgroup, 2018 - Present
Member, Brain Metastasis Clinic Medical Oncology Planning Group, 2018 - Present
Member, Clinical Review Committee (CRC) 1, 2016 - 2020
Member (alternate), Credentials Committee of the Medical Staff, 2016 - 2017
Member, Epic Oncology History Advisory Group, 2015 - 2016
Member, Epic Staging Advisory Group, 2014 - Present
EHR Officer, EPIC, 2014 - Present
Peer-Nominated Representative, House Staff Senate, 2013 - 2014
Coordinator, Journal Club Series, 2013 - 2014
Consultantships
Consultant, Apellis Pharmaceuticals Inc, Houston, 2023 - Present
Member, Data Safety Monitoring Board, Plus Therapeutics, Houston, 2022 - Present
Data Safety Monitoring Board (DSMB), Plus Therapeutics, Houston, 2022 - Present
Advisory Board, Kadmon Corporation, LLC, New York, NY, 2016 - 2016
Advisory Board, AbbVie Inc, Chicago, IL, 2016 - 2017
Advisory Board, Monteris Medical Corporation, Orlando, FL, 2016 - 2016
Advisory Board, California Institute for Regenerative Medicine (CIRM), California, 2015 - Present
Honors & Awards
| 2022 | Brain Mets Clinic 5% Effort Support, Brain Metastasis Stride Account |
| 2022 | Top 10% national ranking provider for patient experience |
| 2016 | Participant, Heart of Leadership Program, MD Anderson Cancer Center, 2016 |
| 2014 | William James Miller Endowed Fellowship Award, MD Anderson Cancer Center |
| 2013 | Nominated Participant, ASCO/AACR Workshop on Methods in Clinical Cancer Research |
| 2012 | Virginia Scola Compassionate Physician Award, University of Connecticut Neurology Residency Program |
| 2011 | First Place Award for Acute Stroke Care Excellence, Hartford Hospital |
| 2010 | Nominated Participant, Neurology Residents Scholar Program, Epilepsy Conference Workshop |
| 2009 | First Place Award, Clinical Skills Simulation, University of Connecticut Internal Medicine Program |
| 2008 | Iota Epsilon Alpha Honor Society Member, St. George's University School of Medicine |
| 2006 | Dean's List, St. George's University School of Medicine |
| 2005 | Dean's List, St. George's University School of Medicine |
| 2004 | A+ Teacher Recognition Bonus, Silver Shores Elementary School |
| 2003 | Exceptional Volunteer Dedication Award, Miami Children's Hospital |
| 2001 | Dean's List, Tulane University |
| 1997 | Academic Scholarship, Tulane University |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Singh AP, Xiao L, O'Brien BJ, Blondeau CE, Flowers CR, Bruera E, Morris VK, Shah AY.. Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study. JCO Oncology Practice, 2023. PMID: 37235818.
- Singh AP, Xiao L, O'Brien BJ, Blondeau CE, Flowers CR, Bruera E, Morris VK, Shah AY.. Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study. JCO Oncol Pract, 2023. PMID: 37235818.
- Oliva G, Ferguson S, Bassett R, Foster A, John I, Hennegan T, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Amaria R, Wong M, Diab A, Yee C, Patel S, McQuade J, Fischer G, McCutcheon I, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA.. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nature Medicine 29(4):898-905, 2023. PMID: 36997799.
- Ozkizilkaya HI, Johnson JM, O'Brien BJ, McCutcheon IE, Prabhu SS, Ghia AJ, Fuller GN, Huse JT, Ballester LY.. Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle. Neurooncology Adv 5(1), 2023. PMID: 37051329.
- Le Rhun E, Devos P, Winklhofer S, Lmalen H, Brandsma D, Kumthekar P, Castellano A, Compter A, Dhermain F, Franceschi E, Forsyth P, Furtner J, Galldiks N, Pérez-Larraya JG, Gempt J, Hattingen E, Hempel JM, Lukacova S, Minniti G, O'Brien B, Postma TJ, Roth P, Rudà R, Schaefer N, Schmidt NO, Snijders TJ, Thust S, van den Bent M, van der Hoorn A, Vogin G, Smits M, Tonn JC, Jaeckle K, Preusser M, Glantz M, Wen PY, Bendzsus M, Weller M.. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. Neuro Oncol 24(10):1726-1735, 2022. e-Pub 2022. PMID: 35157772.
- Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. PMID: 36128585.
- de Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien BJ, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB.. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology(11(2)):CNS87, 2022. PMID: 35575067.
- de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O'Brien BJ, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neurooncology Adv 4(1), 2022. PMID: 35611270.
- Harrison RA, Ou A, Naqvi SMAA, Naqvi SM, Weathers SS, O'Brien BJ, de Groot JF, Bruera E.. Aggressiveness of care at end of life in patients with high-grade glioma. Cancer Medicine 10(23):8387-8394, 2021. PMID: 34755486.
- Palmisciano P, Haider AS, Nwagwu CD, Wahood W, Yu K, Ene CI, O'Brien BJ, Aoun SG, Cohen-Gadol AA, El Ahmadieh TY. The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review. Neuro-Oncology Advances 41(11):5333-5342, 2021. e-Pub 2021. PMID: 34732403.
- Walker JG, Armstrong TS, O'Brien BJ, Gilbert MR, Casareze RL, Fagundes C, Heijnenc CJ, Andersen CR, Yuan Y, Wu J, Biondo-Woode G.. Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis. Comprehensive Psychoneuroendocrinology 8, 2021. e-Pub 2021. PMID: 100099.
- Gogia B, Young AL, O'Brien BJ, Okhuysen PC, Kumar VA.. Bihemispheric Cortical Infarcts in an Adult Secondary to Escherichia coli K1 Meningitis. Case Rep Neurol 13(2):572-577, 2021. e-Pub 2021. PMID: 34720964.
- Giridharan N, Glitza Oliva IC, O'Brien BJ, Parker Kerrigan BC, Heimberger AB, Ferguson SD. Targeting the Tumor Microenvironment in Brain Metastasis. Neurosurg Clin N Am 31(4):641-649, 2020. PMID: 32921358.
- Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd NK, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB.. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research, 2020.
- Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB.. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. CLin Cancer Res 26(14):3565-3577, 2020. e-Pub 2020. PMID: 32299815.
- O’Brien BJ, Yust-Katz S, Vera E, Acquaye A, Weller M, Armstrong T.. Burnout and career satisfaction in neuro-oncology: a survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology memberships. Neuro-Oncology 22(6):838-850, 2020.
- Saltijeral SN, Grosu HB, De La Garza H, O'Brien BJ, Iliescu G.. Leptomeningeal Enhancement due to Neurosarcoidosis Mimicking Malignancy. Case Rep Med, 2020. e-Pub 2020. PMID: 32373180.
- de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB.. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. NeuroOncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.
- Ferguson SD, Bindal S, Bassett RL Jr, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC.. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142(3):499-509, 2019. e-Pub 2019. PMID: 30847840.
- Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer(112):83-93, 2019. PMID: 30951926.
- Ferguson SD, Bindal S, Bassett RL Jr, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC.. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). Journal of Neuro-Oncology, 2019. PMID: 30847840.
- Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine 25(3):477-486, 2019. e-Pub 2019. PMID: 30742122.
- Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. American Cancer Society 125(3):424-433, 2019. e-Pub 2018. PMID: 30359477.
- Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.. Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
- Walker J, O'Brien BJ, Vera E, Armstrong T.. Describing symptom burden and functional status at the diagnosis of leptomeningeal metastasis. Oncology Nursing Forum 45(3):372-379, 2018. PMID: 29683126.
- Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF.. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Neuro-Oncology 129(3):487-494, 2016. e-Pub 2016. PMID: 27406589.
- Ladha H, Pawar T, Gilbert MR, Mandel J, O-Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong TS. Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol 124(3):501-6, 2015. e-Pub 2015. PMID: 26298437.
Invited Articles
- Nam JY, O'Brien BJ.. Current chemotherapeutic regimens for brain metastasis treatment. Clin Exp Metastasis 34(6-7):391-399, 2017. e-Pub 2017. PMID: 28918542.
- O'Brien BJ, Colen RR. Post-treatment Imaging Changes in Primary Brain Tumors. Curr Oncol Rep 16(8):397, 2014. PMID: 24997979.
Other Articles
- O'Brien BJ New hope for leptomeningeal disease care. Cancerwise Blogs, 2017.
- O'Brien BJ Coping with a brain tumor. Cancerwise Blogs, 2016.
Abstracts
- Bradshaw M, Wefel J, Noll K, Rao G, Ferguson S, Tawbi H, Huse J, Johnson J, Court L, O'Brien BJ, Lang F, Ejezie L, Sullaway C, Thomas A, Suki D, Yeboa DN.. NCOG-01. Baseline patient-reported outcomes in an ongoing phase lll trail of pre-operative srs versus post operative srs for brain metastases. Neuro-Oncology 25(Suppl 5):v213, 2023.
- Majd N, Yeboa DN, Weathers SP, Yuan Y, Robichaux C, Al Anssari H, Gachimova E, Loghin M, Kamiya-Matsuoka C, O'Brien BJ, Aaroe A, Patel C, Yung WKA, Wintermark M, Gule M, Ferguson S, Puduvalli V, de Groot J.. CTNI-42. Phase l clinical trail of peposertib plus radiation in newly diagnosed mgmt-unmethylated glioblastoma. Neuro-Oncology 25(Suppl 5):v84, 2023. e-Pub 2023.
- Weathers S, Kamiya-Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova E, Aaroe A, Patel C, Loghin M, O'Brien BJ, Yung WKA, Puduvalli V, de Groot J.. CTIM-23. Safety run-in results of a phase l/ll study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma. Neuro-Oncology 25(Suppl 5):v67, 2023.
- Kamiya-Matsuoka C, Weathers S, Yung WKA, Monica L, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, de Groot J, O'Brien BJ.. CTNI-78. Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM mgmt-unmethylated patients. Neuro-Oncology 25(Suppl 5):v95-v96, 2023.
- Rodriguez A, Wang C, Loghin M, Guha-Thakurta N, O'Brien B.. SDPS-43 Outcomes of supratentorial focal enhancing lesions concerning for leptomeningeal metastases. Neuro-Oncology Advances 5 (suppl 3):iii25, 2023.
- Wefel J, Noll K, Rao G, Ferguson S, Tawbi H, Huse J, Johnson J, Court L, O'Brien BJ, Lang F, Ejezie L, Sullaway C, Thomas A, Suki D,Yeboa DN.. TIPS-15 Neurocognitive function and neurocognitive concerns in an ongoing phase lll trial of pre-operative srs versus post-operative srs for brain metastases. Neuro-Oncology Advances 5 (Suppl 3):iii37, 2023.
- Gilbert MR, Omuro A, Yuan Y, Mendoza T, Wall K, Grajkowska E, Vera E, Reyes J, Aldape K, Penas-Prado M, Walbert T, Mikkelsen T, Weathers S, O'Brien BJ, de Groot J, Puduvalli V, Pentsova E, DeAngelis L, Kaley T, Gavrilovic I, Batchelor T, Armstrong TS.. JS01. A phase 2 trial of cardboplatin and bevacizumab for recurrent adult ependymoma. A cern study. Neuro-Oncology 25(Suppl 2):ii7, 2023.
- Gregory T, Knight S, Aaroe A, O'Brien BJ, Patel C, Weathers S, Majd N, Puduvalli V, Kamiya-Matsuoka C.. Analysis of tumor progression among patients with glioma after COVID-19 infection. Journal of Clinical Oncology 41(Suppl 16), 2023. e-Pub 2023.
- de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien BJ, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC.. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neurooncol Adv 4(1), 2022. PMID: 35611270.
- O'Brien BJ, Penas-Prado M, Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Harrison R, Majd NK, Knight S, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, DeGroot JF. CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING. Neuro-Oncology 23(suppl 6):vi65, 2021. e-Pub 2021.
- Weathers S, Knafl M, Parra E, Hernandez S, Solis L, Sanchez Espiridion B, Wistuba I, Futreal A, Maru D, Kamiya-Matsuoka C, Harrison R, Joseph V, Yun C, Darbonne W, Loghin M, Penas-Prado M, Majd N, Yung WKA, O'Brien BJ, Scott W, DeGroot JF.. CTIM-04. BIOMARKER IMMUNE CORRELATES IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ATEZOLIZUMAB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION. Neuro-Oncology 23(suppl 6):vi49, 2021. e-Pub 2021.
- Pham L, Gann C, Maria Schumacher K, Vlassak S, Swanson T, Highsmith K, Ou A, Clarke N, Aaroe A, Robell L, O'Brien BJ, Nash S, DeGroot JF, Majd NK.. INNV-21. COMPLETE RESPONSE TO ADJUVANT TEPOTINIB IN A PATIENT WITH NEWLY DIAGNOSED DISSEMINATED GLIOBLASTOMA (GBM) HARBORING MET AMPLIFICATION. Neuro-Oncology 23(suppl 6):vi109, 2021. e-Pub 2021.
- Rhun EL, Devos P, Winklhofer S, Lmalem H, Brandsma D, Gállego Pérez-Larraya Z, Castellano A, Compter A, Dhermain F, Franceschi E, Forsyth P, Furtner J, Galldiks N, Gempt J, Glantz M, Hattingen E, Martin Hempel J, Jaeckle K, Kumthekar P, Lukacova S, Minniti G, O'Brien BJ, Postma TJ, Roth P, Rudà R, Schäfer N, Ole Schmidt N, Smits M, Snijders T, Thust S, Tonn JC, van den Bent M, van den Hoorn A, Vogin G, Preusser M, Wen P, Bendszus M, Weller M.. NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology 23(suppl 6):vi126-vi127, 2021. e-Pub 2021.
- Upadhyay R, Khose S, Pokhylevych H, Paulino ADC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien BJ, Kamiya-Matsuoka C, DeGroot JF, Puduvalli V, Tatsui C, Prabhu S, Zaky W, Lin F, Weinberg J, Rhines L, Fuller G, Sandberg D, Johnson JM, McGovern S.. RADT-09. ROLE OF RADIOTHERAPY IN MANAGEMENT OF PRIMARY SPINAL HIGH GRADE GLIOMA: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS. Neuro-Oncology 23(suppl 6):vi42-vi43, 2021. e-Pub 2021.
- Palmisciano P, Haider AS, Nwagwu CD, Wahood W, Sagoo NS, Yu K, Ene CI, O’Brien BJ, Cohen-Gadol AA, El Ahmadieh TY. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review. Neuro-Oncology Advances 3(suppl 3):iii9, 2021. e-Pub 2021.
- Palmisciano P, Haider AS, Nwagwu CD, Wahood W, Sagoo NS, Yu K, Ene CI, O’Brien BJ, Cohen-Gadol AA, Ahmadieh T.. LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review. Neuro-Oncology Advances 3(Suppl 3), 2021.
- Stringer-Reasor EM, O'Brien BJ, Topletz-Erickson A, White JB, Lobbous M, Riley K, Childress J, LaMaster K, Melisko ME, Morikawa A, de Groot JF, Krop IE, Valero V, Rimawi MF, Wolff AC, Tripathy D, Lin NU, Murthy RK.. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Journal of Clinical Oncology 39(suppl 15):1044-1044, 2021. e-Pub 2021.
- Murthy RK, O'Brien BJ, Berry DA, Singareeka-Raghavendra A, Gule Monroe M, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikawa A, Ferguson S, de Groot JF, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin NU, Stringer-Reasor E.. Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. San Antonio Breast Cancer Symposium (SABCS)(PD4-02), 2021. e-Pub 2021.
- O’Brien BJ, Murthy RK, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morkikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park DM, Park BH, Krop I, Lin NU, Rimawi MF, Wolff A, Forero-Torres A, Stringer-Reasor E. TBCRC 049: Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Society for Neuro-Oncology, 2021. e-Pub 2021.
- Ashley Aaroe MD, D3CODE Team, Rebecca Harrison MD, Nazanin Majd MD, Barbara O’Brien MD, John de Groot MD, Karin Woodman MD. A snapshot of the impact of COVID-19 on patients with nervous system tumors. Abstract #: COVD-30. Society for Neuro-Oncology Annual Meeting, 2020.
- Gogia B, Kumar VA, O’Brien BJ.. P13.10-017 Bihemispheric Cortical Infarcts in a Patient with E.Coli Meningitis. Neurology 95(4), 2020.
- Weathers SS, Kamiya-Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd NK, Yung WKA, O'Brien BJ, De Groot JF.. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology 38 (suppl; abstr 2511), 2020.
- Weathers SS, Penas-Prado M, Banerjee PP, Bdiwi M, Shaim H, Alsuliman A, Shanley M, Long J, de Groot JF, O'Brien BJ, Majd NK, Harrison RA, Kamiya-Matsuoka C, Fuller GN, Chi L, Rao G, Lang FF, Shpall EJ, Rezvani K, Heimberger AB.. A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function. Journal of Clinical Oncology 38 (suppl; abstr 2515, 2020.
- Glitza IC, Phillips S, Brown C, Haymaker CL, Bassett RL, Lee JJ, Rohlfs ML, Richard J, Iqbal M, John I, McCutcheon IE, Ferguson SD, Heimberger AB, O'Brien BJ, Tummala S, Guha-Thakurta N, Debnam M, Burton EM, Tawbi HA, Davies MA.. Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). Journal of Clinical Oncology 38 (suppl; abstr 10008), 2020.
- Murthy RK, O’Brien BJ, Hess KR, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morkikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park D, Park BH, Krop I, Lin NU, Wolff A, Forero-Torres A, Stringer-Reasor E.. a phase ii non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in her2 positive breast cancer tbcrc049. San Antonio Breast Cancer Aymposium, 2019.
- O’Brien BJ, Penas-Prado MKamiya-Matsuoka C, Weathers SP, Yung WKA, Loghin M, Harrison R, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, de Groot J. ACTR-12 Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naive glioblastoma in the recurrent and adjuvant setting. Neuro Oncology 21(Supplement 6), 2019.
- Metrus N, Kamiya C, Weathers SP, Seligman C, O’Brien BJ. CMET-34. Improvement of leptomeningeal disease following infectious meningitis. Neuro Oncology 21(Supplement 6):vi59, 2019.
- Acquaye AA, Vera E, O’Brien BJ, Yust-Katz S, Venere M, Chheda MG, Lee E, Armstrong TS.. Abstract 150 SNOCares: Addressing Burnout in Neuro-Oncology Professionals Through Awareness & Education. Journal of Psychosocial Oncology and Practice 1(1S):e10, 2019.
- Sinicrope KD, Barata P, Walker J, Tremont-Lukats IW, Groves I, Loghin M, Seligman C, Ferguson S, Weathers SP, Penas-Prado M, Kamiya-Matsuoka C, Harrison R, Tummala S, Trevino CR, Peinado S, Murthy RK, Seyedeh D, de Groot JF, O’Brien BJ.. LPTO-09. Intrathecal topotecan for leptomeningeal metastasis in solid tumors: The MD Anderson Experience. Neuro-Oncology Advances 1(suppl 1):i8, 2019.
- Trevino CR, Murthy RK, Singareeka Raghavendra A, Loghin M, Seligman C, Ferguson S, Kamiya-Matsuoka C, Harrison R, Sinicrope KD, Valero V, Tummala S, Hess K, Tripathy D, de Groot J, O’Brien BJ.. LPTO-08. Intrathecal trastuzumab plus/minus it topotecan for patients with her2+ breast cancer and leptomeningeal metastasis. Neuro-Oncology Advances 1(suppl 1):i7-i8, 2019.
- Li J, Lang FF, Guha-Thakurta N, Weinberg JS, Rao G, Heimberger A, Ferguson S, Prabhu S, Sawaya R, Yeboa DN, McAleer MF, Chung C, Briere T, Davies M, de Groot J, Glitza I, Murthy RK, Rodon J, O’Brien BJ, Dumbrava E, Yung WKA, Vining D, Schomer D, Wang Y, Suki D, Wozny M, Zaebst D, Austin W, Nguyen A, Burton E, Davis S, Tawb HI.. MLTI-10. Establishment of a multidisciplinary brain metastasis clinic to facilitate patient-centered care and coordinated research. Neuro-Oncology Advances 1(suppl 1):i16, 2019.
- O'Brien BJ, de Groot J, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, and Penas-Prado M.. Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma. Proceedings: AACR Annual Meeting 2019, 2019.
- de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O’Brien BJ, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WK A, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology 20(Supplement 6):vi2, 2018.
- Metrus N, Daher A, Harrison R, Majd N, Maraka S, Nam J, Trevino C, Weathers SP, O’Brien BJ, Kamiya-Matsuoka C, Loghin M, Alfaro K, Hunter K, Yung WK, de Groot J, Penas-Prado M.. INNV-15. Analysis of challenges to accrual in clinical trials for newly diagnosed glioblastoma. Neruo-Oncology 20(Supplement 6):vi141, 2018.
- de Groot JF, Penas-Prado M, Mandel J, O'Brien BJ, Weathers SP, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse J, Rao G, Weinberg J, Prabhu S, Ferguson S, Yuan Y, Vence L, Allison J, Sharma P, Heimberger A.. ATIM-07. Window of opportunity clinical trial of pembrolizumab in recurrent glioblastoma patients. Neuro-Oncology 20(Supplement 6):vi2, 2018.
- Penas-Prado M, Weathers SP, Zhou S, Kamiya-Matsuoka C, O'Brien BJ, Loghin M, Harrison R, Pei B, Ictech S, Hunter K, Yung WK, de Groot J, Shpall E, Heimberger A, Rezvani K.. ATIM-10. A phase I/II clinical trial of autologous CMV- specific cytotoxic t cells (cmv-tc) for glioblastoma: Dose escalation and correlative results. Neuro-Oncology 20(Supplement 6):vi2-vi3, 2018.
- Weathers SP, Kamiya-Matsuoka C, Dervin S, Yun C, Loghin M, O'Brien BJ, Harrison R, Yung WK, Penas-Prado M, de Groot J.. ATIM-37. Safety run-in results of phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (ATEZO; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newlu diagnosed glioblastioma (GBM). Neuro-Oncology 20(Supplement 6):vi9-vi10, 2018.
- O'Brien BJ, de Groot J, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, Penas-Prado M.. ACTR-27. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with mgmt-unmethylated, bevacizumab-naive recurrent glioblastoma. Neuro-Oncology 20(Supplement 6):vi17, 2018.
- O'Brien BJ, Bacha JA, Brown DM, Steino A, Schwartz R, Kanekal S, Lopez L, Penas-Prado M.. Abstract CT054: Phase II study of dianhydrogalactitol in patients with MGMT-unmethylated bevacizumab-naive recurrent glioblastoma. Proceedings: AACR Annual Meeting 2017, 2018.
- O'Brien BJ, de Groot J, Kamiya-Matsuoka C, Weathers SP, Bacha JA, Brown DM, Steino A, Langlands J, Schwartz R, Kanekal S, Lopez L, and Penas-Prado M.. Abstract CT167: Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated. Proceesings: AACR Annual Meeting 2018, 2018.
- Oikawa M, Ramesh N, Sei E, Bai S, Hu M, de Groot JF, Murthy R, O'Brien BJ, Navin N.. Noninvasive genomic profiling of cerebral spinal fluid in breast cancer patient with leptomeningeal disease. Proceedings: AACR Annual Meeting 2018, 2018.
- Maraka S, Bastos D, O’Brien BJ, Liu DD, Starostina O, Alfaro-Munoz K, Ganesh R, De Groot J, Prabhu S. Laser interstitial thermotherapy (LITT) for newly diagnosed and recurrent glioblastoma: Safety, effectiveness and association between time to initiation of chemotherapy post-procedure and outcome. Neurology 90(Supplement 15):P4.155, 2018.
- Bacha J, Steino A, Langlands J, Kanekal S, Schwartz R, Lopez L, O’Brien BJ, Chen Z, Penas-Prado M, Brown D.. ACTR-50. Clinical Trials with Dianhydrogalactitol(VAL-083) in MGMT-Unmethylated Glioblastoma. Neuro-Oncology 19(6):vi11, 2017.
- Kamiya-Matsuoka C, Shaw K, Loghin M, Penas-Prado M, O’Brien BJ, Weathers S, Alfaro-Munoz K, Yung WK, de Groot JF.. PATH-37. The natural Course of Hypermutator Gliomas . Neuro-Oncology 19(6):vi179, 2017.
- Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Barastianos PK, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, Ibrahim N, de Groot JF, McCarty J, O’Brien BJ, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A.. CMET-09. Pan-Cancer Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Neuro-Oncology 19(6):vi40-vi41, 2017.
- Maraka S; Bastos DC; O’Brien BJ; Liu D; Starostina O; Alfaro-Munoz K; Rao G; de Groot J; Prabhu SS. SURG-11. Laser Interstitial Thermotherapy (LITT) for Newly Diagnosed and Recurrent Glioblastoma: Association Between Time to Initiation of Chemotherapy Post-Procedure and Outcome. Neuro-Oncology 19(6):vi237-vi238, 2017.
- Acquaye AA, Vera E, Yust-Katz S, O’Brien BJ, Armstrong T.. QLIF-02. Neuro-Oncology Burnout: Impact of Professional Stressors and Job Satisfaction. Neuro-Oncology 19(6):vi201, 2017.
- Yust-Katz S; O'Brien BJ; Vera E; Acquaye AA; Vera E; Armstrong TS. QLIF-39. Burnout for Neuro-Oncology Professionals. Neuro-Oncology 19(6):vi210, 2017.
- Walker J; O’Brien BJ; Armstrong TS; Gilbert MR; Casarez R; Wood G. QLIF-45. Associations Among Meaning of Illness, Symptom Burden, Quality of Life and Depression in Patients with Leptomeningeal Metasases. Neuro-Oncology 19(6):vi211, 2017.
- O'Brien BJ, Yust-Katz S, Vera E, Acquaye AA, Armstrong TS.. QLIF-30. Rick factors for burnout among Neuro-Oncology providers: A predictive model. Neuro-Oncology 19(suppl 6):vi207-vi208, 2017.
- Nam J, Harrison RA, Fuller G, Johnson J, O'Brien BJ. A Clinical, Radiologic, and Pathologic Review of Astroblastoma: The MD Anderson Experience. American Academy of Neurology, 2017.
- Nam JY, Harrison RA, Weathers SS, Pillainayagam C, de Groot JF, Kamiya Matsuoka C, Yung WK, Li J, Ferguson SD, O'Brien BJ.. Association of Clinical Phenotype and Treatment History with Survival in Adult Brainstem Glioblastoma. Journal of Clinical Oncology, 2017.
- Bacha JA, Steino A, Schwartz RS, Langlands J, Kanekal S, Lopez L, O'Brien BJ, Chen Z, Penas-Prado M, Brown D. Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma. Journal of Clinical Oncology, 2017.
- Yust-Katz S, O’Brien BJ, Acquaye AA, Armstrong TS.. OS05.2 Burnout and Career Satisfaction among Neuro-Oncology Health Care Providers: An International Survey. Neuro-Oncology 19(3):iii9, 2017.
- Yust-Katz S, O'Brien BJ, Vrea E, Acquaye A, Weller M, Armstrong T. Burnout and Career Satisfaction in Neuro-Oncology: A Survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology Membership. Neuro Oncology 19(Supplement 3):iii9, 2017.
- Harrison RA, Nam JY, Fuller GN, Johnson JM, O’Brien BJ. RARE-61. Clinical, Radiologic, and Pathologic Review of Astroblatoma: The MD Anderson Experience. Neuro-Oncology 18(Supplement 6):Vi171, 2016.
- O'Brien BJ, Bacha JA, Brown DM, Steino A, Schwartz R, Kanekal S, Lopez LM, and Penas-Prado M. 1Phase II study of dianhydrogalactitol in patients with MGMT-unmethylated, bevacizumab-naive recurrent glioblastoma. Abstract 155, CNO meeting, June 2016, 2016.
- Harrison R, Masood A, Mawlawi O, Schellingerhout D, Chasen B, Millican R, Li J, O’Brien BJ, Johnson J. Evaluation of delayed FDG-PET in differentiating progressive disease from pseudoprogression in brain tumors. Abstract 219, CNO meeting, June 2016, 2016.
- Armstrong T, Payen S, Vera E, Acquaya A, Alfaro-Munoz K, Nielsen D, Penas-Prado M, Weathers SP, O'Brien BJ, and de Groot J. PALL-03. The Impact of Molecular Diagnostics on Function and Symptom Burden in Glioma Patients. Neuro-Oncology 18(Supplement 6), 2016.
- Walker J, O'Brien BJ, Vera E, and Armstrong T. QLIF-13. Describing Symptom Burden and Functional Status at Diagnosis of Leptomeningeal Metastasis. Neuro-Oncology(Supplement 6), 2016.
- Walker J, Tremont I, O'Brien BJ, Armstrong T.. QOL-26 Describing symptom burden in patients with leptomeningeal metastases: selecting an instrument. Neuro-Oncology 17(Supplement 5):v193-v194, 2015.
- Barata PM, Kamiya Matsuoka C, Kim SL, Loghin ME, O'Brien BJ, Tremont-Lukats I.. Outcomes after hospitalization in patients with recurrent glioblastoma. Journal of Clinical Oncology 33(15_suppl), 2015.
- Weathers SP, Han SX, Liu DD, Conrad CA, Gilbert MR, Loghin M, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WK, de Groot JF.. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. Journal of Clinical Oncology 33(Supplement; Abstract 2005), 2015.
- Oughli HA, Balakrisgnan N, Munsell MF, Shiozaki T, Frumovitz MM, Soliman PT, Schmeler KM, Ramirez PT, Nick AM, O'Brien BJ, Westin SN.. Paraneoplastic neurologic syndrome in ovarian carcinoma. Gynecologic Oncology, 2015.
- Pawar TU, Ladha HA, Mandel JA, Gilbert MR, O'Brien BJ, Hamza MO, Armstrong TE. CN-15 Adverse Effects of Bevacizumab in Brain Tumor Patients. Neuro-Oncology 16(Supplement 5):v49, 2014.
- Ladha HA, Pawar TU, Gilbert MA, O'Brien BJ, Conrad CH, Fields MA. Hanna TE, Loch CA, Armstrong TE. AI-18 Wound Healing Complications in A Series of Brain Tumor Patients On Bevacizumab. Neuro-Oncology 16(Supplement 5):v5, 2014.
- O’Brien BJ, Mandel JJ, Tummala S, de Groot JF. Non-convulsive Status Epilepticus in Cancer Patients with Altered Mental Status. Journal of Clinical Oncology 32, 2014.
- Hamza MA, O’Brien BJ, Mandel JJ, de Groot JF. Survival Outcomes of Patients with Recurrent Anaplastic Glioma Treated with Bevacizumab. Neuro-Oncology 15(iii):98-135, 2013.
- O’Brien BJ, Murthy RK, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morkikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park DM, Park BH, Krop I, Lin NU, Rimawi MF, Wolff A, Forero-Torres A, Stringer-Reasor E.. TBCRC049: A phase II study to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis in HER2 positive breast cancer. Society for Neuro-Oncology.
Book Chapters
- Ou A, O’Brien BJ.. Neurological Complications of Breast Cancer. In: Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Second. Newton/Malkin, 2020.
- Weathers SP, O’Brien BJ, de Groot JF. Tumors of the Central Nervous System. In: The MD Anderson Manual of Medical Oncology. 3rd, 829-856, 2016.
- Weathers SP, O’Brien BJ, Yung WK, de Groot JF. Chapter 18: Targeted Therapy in Solid Tumors: Brain. In: Targeted Therapy in Cancer. Wiley, 2015.
- O’Brien BJ, Gilbert MR. Primary Brain Tumors. In: Cancer Consult: Expertise for Clinical Practice. Wiley-Blackwell Health Sciences, 449-456, 2014.
- O’Brien BJ, Yung WK, de Groot JF. Small-molecule-based Therapies. In: Essentials of Neuro-oncology. 3rd. Thieme, 234-244, 2014.
Grant & Contract Support
| Title: | Longitudinal CSF and Blood Monitoring of Genomic Alterations in Patients with Glioma |
| Funding Source: | Moonshot |
| Role: | Principal Investigator |
| Title: | Phase II Study of Single-Agent Crenolanib in Recurrent/Refractory Glioblastoma with PDGFRA |
| Funding Source: | Arog Pharmaceuticals, LLC |
| Role: | Principal Investigator |
| Title: | Phase 2, Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment with a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases |
| Funding Source: | Kadmon Corp., LLC |
| Role: | Principal Investigator |
| Title: | Phase II study of VAL-083 in patients with MGMT unmethylated, bevacizumab-naive recurrent |
| Funding Source: | DelMar Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Pilot Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma |
| Funding Source: | Monteris Medical |
| Role: | Principal Investigator |
| Title: | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) |
| Funding Source: | National Cancer Institute |
| Role: | Co-Principal Investigator |
| Title: | Feasibility Study on Laser Interstitial Thermal Therapy (LITT) in Glioblastoma |
| Funding Source: | Monteris Medical |
| Role: | Principal Investigator |
| Title: | A Phase II, Non-Randomized Study to Assess the Efficacy and Safety of the Combination of ONT-380 plus Capecitaabine or Trastuzumab for Leptomeningeal Metastases in Patients with Advanced HER2+ Breast Cancer |
| Funding Source: | Johns Hopkins University |
| Role: | Co-Principal Investigator |
| Title: | Melanoma SPORE (1P50CA221703-01A1), Project 2 (IT/IV nivolumab for LMD) |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Title: | UT SPORE in Lung Cancer Enhancement Research award, Assessment of CNS metastases in SCLC animal models and CSF-based liquid biopsies |
| Funding Source: | MD Anderson Cancer Center |
| Role: | Significant Contributor |
| Title: | The University of Texas MD Anderson Cancer Center Melanoma SPORE Project 2 Intrathecal Anti-PD-1 Immunotherapy for Metastatic Melanoma Patients with Leptomeningeal Disease (LMD) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
Patient Reviews
CV information above last modified November 22, 2024